{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:42:04Z","timestamp":1792791724175,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06880"],"award-info":[{"award-number":["22K06880"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K18508"],"award-info":[{"award-number":["24K18508"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cellsig.2025.112156","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:22:32Z","timestamp":1759339352000},"page":"112156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["METTL3 contributes to osimertinib resistance in non-small cell lung cancer cell lines by regulating CDC25A and AURKB mRNA stability"],"prefix":"10.1016","volume":"136","author":[{"given":"Ryusuke","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Meguro-Horike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Horike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasithorn","family":"Wanna-udom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Takino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cellsig.2025.112156_bb0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2025.112156_bb0010","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.cellsig.2025.112156_bb0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.trecan.2020.11.005","article-title":"Targeting infrequent driver alterations in non-small cell lung Cancer","volume":"7","author":"Nokin","year":"2021","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.cellsig.2025.112156_bb0020","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung Cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.cellsig.2025.112156_bb0025","first-page":"109","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.cellsig.2025.112156_bb0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canlet.2018.02.004","article-title":"Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies","volume":"420","author":"Tang","year":"2018","journal-title":"Cancer Lett."},{"issue":"18","key":"10.1016\/j.cellsig.2025.112156_bb0035","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","article-title":"Tacklin Osimertinib resistance in EGFR-mutant non-small cell lung Cancer","volume":"29","author":"Blaquier","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","article-title":"The role of m6A modification in the biological functions and diseases","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40364-021-00278-9","article-title":"Novel insights into the m6A-RNA methyltransferase METTL3 in cancer","volume":"9","author":"Cai","year":"2021","journal-title":"Biomark. Res."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112156_bb0050","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-18-2965","article-title":"The critical role of RNA m6A methylation in Cancer","volume":"79","author":"Lan","year":"2019","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.cellsig.2025.112156_bb0055","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.21037\/tlcr-24-85","article-title":"Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applications","volume":"13","author":"Su","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12890-022-02119-3","article-title":"METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way","volume":"22","author":"Dou","year":"2022","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13578-024-01194-9","article-title":"METTL3 drives NSCLC metastasis by enhancing CYP19A1 translation and oestrogen synthesis","volume":"14","author":"Meng","year":"2024","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112156_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3892\/or.2021.8114","article-title":"METTL3-mediated m6A modification of Bcl-2 mRNA promotes non-small cell lung cancer progression","volume":"46","author":"Zhang","year":"2021","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2020.01.042","article-title":"The m6A methyltransferase METTL3 contributes to transforming growth factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB","volume":"524","author":"Wanna-Udom","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112156_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3397","article-title":"The pathological tissue expression pattern and clinical significance of m6A-regulatory genes in non-small cell lung cancer","volume":"24","author":"Li","year":"2022","journal-title":"J. Gene Med."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13046-021-02137-9","article-title":"M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way","volume":"40","author":"Li","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41420-021-00488-y","article-title":"N6-methyladenosine (m6A) methyltransferase KIAA1429 accelerates the gefitinib resistance of non-small-cell lung cancer","volume":"7","author":"Tang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cellsig.2025.112156_bb0095","article-title":"m6A reader IGF2BP3 contributes to gefitinib resistance in lung adenocarcinoma cells by modulating SNAI2 expression","volume":"38","author":"Takatsuka","year":"2025","journal-title":"Gene Rep."},{"issue":"22","key":"10.1016\/j.cellsig.2025.112156_bb0100","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.3390\/cancers14225582","article-title":"N6-Methyladenosine modification of CIRCKRT17 initiated by METTL3 promotes Osimertinib resistance of lung adenocarcinoma by EIF4A3 to enhance YAP1 stability","volume":"14","author":"Ji","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.cellsig.2025.112156_bb0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1042\/BJ20110343","article-title":"PLU1 histone demethylase decreases the expression of KAT5 and enhances the invasive activity of the cells","volume":"437","author":"Yoshida","year":"2011","journal-title":"Biochem. J."},{"issue":"13","key":"10.1016\/j.cellsig.2025.112156_bb0110","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4161\/cc.25142","article-title":"KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family","volume":"12","author":"Enkhbaatar","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cellsig.2025.112156_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2023.05.061","article-title":"ASH2L, a COMPASS core subunit, is involved in the cell invasion and migration of triple-negative breast cancer cells through the epigenetic control of histone H3 lysine 4 methylation","volume":"669","author":"Batbayar","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"49","key":"10.1016\/j.cellsig.2025.112156_bb0120","doi-asserted-by":"crossref","first-page":"15995","DOI":"10.1002\/anie.201807942","article-title":"An elongation- and ligation-based qPCR amplification method for the radiolabeling-free detection of locus-specific N6 -methyladenosine modification","volume":"57","author":"Xiao","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","article-title":"Roles of METTL3 in cancer: mechanisms and therapeutic targeting","volume":"13","author":"Zeng","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112156_bb0130","article-title":"RNA m6A modification in cancers: molecular mechanisms and potential clinical applications","volume":"1","author":"Gu","year":"2020","journal-title":"Innovation (Camb.)"},{"issue":"7860","key":"10.1016\/j.cellsig.2025.112156_bb0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cellsig.2025.112156_bb0140","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jpha.2023.04.009","article-title":"Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer","volume":"13","author":"Xiao","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"11","key":"10.1016\/j.cellsig.2025.112156_bb0145","doi-asserted-by":"crossref","first-page":"8852","DOI":"10.3390\/cimb45110555","article-title":"STM2457 inhibits the invasion and metastasis of pancreatic cancer by down-regulating BRAF-activated noncoding RNA N6-methyladenosine modification","volume":"45","author":"Hao","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.cellsig.2025.112156_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.833694","article-title":"Transcriptome-wide analysis of RNA N6-methyladenosine modification in adriamycin-resistant acute myeloid leukemia cells","volume":"13","author":"Fang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.cellsig.2025.112156_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117366","article-title":"METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3\/AKT pathway and synergizes with PARP inhibitor","volume":"179","author":"Chen","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112156_bb0160","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.7150\/ijbs.97425","article-title":"Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner","volume":"20","author":"Zhang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112156_bb0165","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112156_bb0170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0175","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1038\/s41467-024-49360-4","article-title":"Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies","volume":"15","author":"Figarol","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41698-022-00337-w","article-title":"The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells","volume":"6","author":"Criscione","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"11","key":"10.1016\/j.cellsig.2025.112156_bb0185","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.7150\/ijbs.98535","article-title":"m6A modification enhances the stability of CDC25A promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle","volume":"20","author":"Pan","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112156_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2024.100697","article-title":"A combined deep learning framework for mammalian m6A site prediction","volume":"4","author":"Fan","year":"2024","journal-title":"Cell Genomics"},{"issue":"9","key":"10.1016\/j.cellsig.2025.112156_bb0195","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","article-title":"Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis","volume":"39","author":"Tanaka","year":"2021","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.cellsig.2025.112156_bb0200","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1021\/jm0102046","article-title":"Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25","volume":"44","author":"Lazo","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2025.112156_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2017.09.023","article-title":"Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth","volume":"410","author":"Al-Matouq","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/mc.20063","article-title":"Regulation of lung cancer cell growth and invasiveness by \u03b2-TRCP","volume":"42","author":"He","year":"2005","journal-title":"Mol. Carcinog."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112156_bb0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/187152012800617678","article-title":"The role of Cdc25A in the regulation of cell proliferation and apoptosis","volume":"12","author":"Shen","year":"2012","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112156_bb0220","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/genes13122183","article-title":"Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung Cancer","volume":"13","author":"Nishihara","year":"2022","journal-title":"Genes (Basel)"},{"issue":"4A","key":"10.1016\/j.cellsig.2025.112156_bb0225","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4236\/jct.2012.324055","article-title":"JNK-mediated FOXO expression plays a critical role in EGFR tyrosine kinase inhibitor-induced BIM expression and apoptosis","volume":"3","author":"Takeuchi","year":"2012","journal-title":"J. Cancer Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112156_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.131","article-title":"NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A","volume":"8","author":"Yuan","year":"2017","journal-title":"Cell Death Dis."},{"issue":"14","key":"10.1016\/j.cellsig.2025.112156_bb0235","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1128\/MCB.21.14.4818-4828.2001","article-title":"The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1","volume":"21","author":"Zou","year":"2001","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112156_bb0240","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12943-022-01680-z","article-title":"Biological and pharmacological roles of m6A modifications in cancer drug resistance","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.cellsig.2025.112156_bb0245","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1513\/pats.200504-037SR","article-title":"Pharmacologic principles for combination therapy","volume":"2","author":"Toews","year":"2005","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"10","key":"10.1016\/j.cellsig.2025.112156_bb0250","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1158\/2159-8290.CD-23-0007","article-title":"Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity","volume":"13","author":"Guirguis","year":"2023","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.cellsig.2025.112156_bb0255","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41375-023-01965-2","article-title":"Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages","volume":"37","author":"Sturgess","year":"2023","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.cellsig.2025.112156_bb0260","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.4155\/bio-2021-0144","article-title":"Review on in vivo profiling of drug metabolites with LC-MS\/MS in the past decade","volume":"13","author":"Reddy","year":"2021","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.cellsig.2025.112156_bb0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1517\/17425255.2012.652084","article-title":"Preclinical in vivo ADME studies in drug development: a critical review","volume":"8","author":"Pellegatti","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"14","key":"10.1016\/j.cellsig.2025.112156_bb0270","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.3390\/ijms23148025","article-title":"Targeted co-delivery of Gefitinib and rapamycin by aptamer-modified nanoparticles overcomes EGFR-TKI resistance in NSCLC via promoting autophagy","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112156_bb0275","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181259","article-title":"Reversal of EGFR inhibitors\u2019 resistance by co-delivering EGFR and integrin \u03b1v\u03b23 inhibitors with nanoparticles in non-small cell lung cancer","volume":"39","author":"He","year":"2019","journal-title":"Biosci. Rep."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825005716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825005716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:46:47Z","timestamp":1781678807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656825005716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"alternative-id":["S0898656825005716"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112156","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"METTL3 contributes to osimertinib resistance in non-small cell lung cancer cell lines by regulating CDC25A and AURKB mRNA stability","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112156"}}